Politics and Clinical Trials: The Inclusion of Women

P and T

Volumn 28, Issue 12, 2003, Pages 791-793+796

  Goldenberg, Marvin M ^a  

^a MMG Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN;

ALZHEIMER DISEASE; BREAST CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG SAFETY; ETHICS; FEMALE; FOOD AND DRUG ADMINISTRATION; GENDER; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEART DISEASE; HIGH RISK POPULATION; HISTORICAL GEOGRAPHIC NAMES; HORMONE SUBSTITUTION; HUMAN; JUSTICE; LAW; LUNG EMBOLISM; POLITICS; PRACTICE GUIDELINE; PROTECTION; REPRODUCTIVE HEALTH; REVIEW; SEX DIFFERENCE; STROKE;

EID: 1242294574     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Food and Drug Administration (FDA), Department of Health, Education, and Welfare. General Considerations for the Clinical Evaluation of Drugs. Washington, DC: Government Printing Office; Report No. HEW 77-3040, 1977.
2. Kessler DA. The regulation of investigational drugs. N Engl J Med 1989;320:281-288.
3. th World Medical Assembly, Helsinki, Finland, June 1964.
4. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Government Printing Office; 1978.
5. Protection of human subjects: Fetuses, pregnant women, in vitro fertilization. No. 45CR46 Subpart B. Federal Register, August 8, 1975.
6. Equal Employment Opportunity, Pregnancy Discrimination Act of 1978, 92 Statute 2076, 42 USC 2000e(k), 29 Code of Federal Regulations (C.F.R.) Part 1604.10. Rules and Regulations, 44, No. 78. Federal Register, April 20, 1979.
7. Herbst AI, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: Association of maternal stilbesterol therapy with tumor appearances in young women. N Engl J Med 1971;284:878-881.
8. Kinney EL, Trautmann J, Gold JA, et al. Underrepresentation of women in new drug trials. Ann Intern Med 1981;95:495-499.
9. U.S. Department of Health and Human Services. (DHHS). Basic DHHS Policy for Protection of Human Research Subjects, 45 Code of Federal Regulations (C.F.R.) Part 46. Bethesda, MD: National Institutes of Health; January 1991.
10. Federal Policy for Protection of Human Subjects. The Common Rule. 56, 28002, Part 46. Federal Register, June 18, 1991.
11. U.S. General Accounting Office (GAO). Women's Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing. Report No. GAO/HRD-93-17. Washington, DC: Government Printing Office; 1992.
12. National Institutes of Health (NIH). Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. NIH Guide, March 18, 1994.
13. Institute of Medicine. Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Vol 1. Washington, DC: National Academy Press; 1994.
14. Food and Drug Administration (FDA). Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. No. 58-FR-39406. Federal Register, July 19, 1993.
15. Merkatz RB, Temple R, Subel S, et al. Women in clinical trials of new drugs: A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med 1993; 329:292-296.
16. Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 2000; 68:510-521.
17. Prout MN, Fish SS. Participation of women in clinical trials of drug therapies: A context for the controversies. Medscape Women's Health eJournal 2001;6(5).
18. NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Notice NOT-OD-02-001. Bethesda, MD: National Institutes of Health; October 9, 2001.
19. Available at www.estrogen-replacement-side-effects.com. Accessed May 2003.
20. Women's Health Initiative (WHI), Department of Health and Human Services, National Institutes of Health, 2003. Available at: www.nhlbi.nih.gov/whi/index/html.
21. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the WHI randomized controlled study. JAMA 2002;288:321-333.
22. Grady D. Study finds new risks in hormone therapy. Available at: www.NYTimes.com. Accessed June 25, 2003.
23. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative memory study: A randomized controlled trial. JAMA 2003;289:2651-2662.